Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | PTPRC | P08575 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520975 | 0.84 | HDAC6 (0.58) | CA1CA2PTPRCCTSLPTPN13 | |
| SCHEMBL436283 | 0.82 | PTPRC (0.52) | CA1CA2PTPRCCTSLPTPN13 | |
| SCHEMBL12553743 | 0.81 | HDAC6 (0.46) | KDM4EMAPTHDAC6SNCAALDH1A1 | |
| SCHEMBL11672759 | 0.81 | EGLN1 (0.61) | CA1CA2PTPRCCTSLPTPN13 | |
| SCHEMBL12553794 | 0.80 | HPGD (0.57) | CA1CA2KDM4EMAPTHDAC6 | |
| SCHEMBL22325377 | 0.79 | ALDH1A1 (0.57) | CA1CA2KDM4EMAPTHIF1A | |
| SCHEMBL11107537 | 0.78 | KDM4E (0.80) | CA1CA2PTPRCCTSLPTPN13 | |
| SCHEMBL3894629 | 0.78 | CNR2 (0.57) | MAPTHDAC6SNCAALDH1A1HPGD | |
| SCHEMBL28703792 | 0.78 | CA12 (0.59) | CA1CA2KDM4EMAPTHDAC6 | |
| SCHEMBL3138286 | 0.77 | TTR (0.53) | CA1CA2PTPRCCTSLPTPN13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4091097-A | A 2'-HYDROXY-3-CARBOXY-4,5-SUBSTITUTED-BENZANILIDE, ITS ESTERS AND SALTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1978-05-23 | — | — | US | disclosed |
| US-4024253-A | BENZANILIDE DERIVATIVES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-05-17 | — | — | US | disclosed |
| US-3973038-A | N-SUBSTITUTED PHENYL 2-HYDROXY BENZAMIDES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | CA1 2423/4885CA2 3018/4885PTPRC 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.